BioCentury | Nov 5, 2019
Company News

Green Valley’s Alzheimer’s drug targeting gut-brain-axis gets Chinese approval

...conditional approval for a gut microbiome-targeting drug from Green Valley to treat mild-to-moderate Alzheimer’s disease. Shanghai Green Valley Pharmaceutical Co. Ltd....
BioCentury | Jul 27, 2018
Clinical News

Green Valley's oligosaccharide meets in Phase III for AD

...Chinese trial enrolled about 788 patients to receive twice-daily 450 mg oral GV-971 or placebo. Shanghai Green Valley Pharmaceutical Co. Ltd....
...Neuropsychiatric Inventory (NPI) Status: Phase III data Milestone: Submit regulatory application (2018) Chris Lieu Beta amyloid Alzheimer's disease (AD) GV-971 Shanghai Green Valley Pharmaceutical Co. Ltd....
Items per page:
1 - 2 of 2
BioCentury | Nov 5, 2019
Company News

Green Valley’s Alzheimer’s drug targeting gut-brain-axis gets Chinese approval

...conditional approval for a gut microbiome-targeting drug from Green Valley to treat mild-to-moderate Alzheimer’s disease. Shanghai Green Valley Pharmaceutical Co. Ltd....
BioCentury | Jul 27, 2018
Clinical News

Green Valley's oligosaccharide meets in Phase III for AD

...Chinese trial enrolled about 788 patients to receive twice-daily 450 mg oral GV-971 or placebo. Shanghai Green Valley Pharmaceutical Co. Ltd....
...Neuropsychiatric Inventory (NPI) Status: Phase III data Milestone: Submit regulatory application (2018) Chris Lieu Beta amyloid Alzheimer's disease (AD) GV-971 Shanghai Green Valley Pharmaceutical Co. Ltd....
Items per page:
1 - 2 of 2